Eloxx Pharmaceuticals, Inc. (ELOX)
Eloxx Pharmaceuticals develops drug candidates for rare genetic kidney and dermatologic diseases. It last closed at $11.74 on Nov 17, down 7.92% on the day. ELOX reports earnings on Fri, Feb 12, 2027. The average 12-month price target from 3 analysts is $36.67 (+212.3% from the last close), with a high of $40.00 and a low of $32.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Key Stats
Fiscal 2025Not reported for this period.
From ELOX's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 16).
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on ELOX in the past 90 days. The average target is $36.67, with a high of $40.00 and a low of $32.00, compared with the last close of $11.74.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 28 | Guggenheim | Target lowered | Buy | $43 → $40 |
| Sep 18 | Leerink Partners | Initiated | Buy | $32 |
| Aug 20 | LUCID CAPITAL MARKETS | Initiated | Buy | $38 |
| Jul 22 | LifeSci Capital | Initiated | Buy | $40 |
| Jul 20 | Guggenheim | Initiated | Buy | $43 |
Technical Analysis
The stock is 11% below its 20 day and 22% below its 50 day average. Momentum is fading (RSI 36), near oversold. The nearest support is the swing low (Nov 9) at $11.66, and the nearest resistance the Pivot at $12.09.
| RSI (14) | 36.15 | Weak, oversold below 30 | Neutral |
| MACD | -0.45 | Above its signal line | Bullish |
| Stochastic | 39.9 | Middle of its range | Neutral |
| ADX (14) | 22.9 | Weak trend | |
| Williams %R | -91.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -252.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −9.1% | Change over 10 sessions | Bearish |
| ATR (14) | $1.17 | Typical daily range, 9.9% of price |
What happened before
See how ELOX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in ELOX in the last 90 days.
ELOX Institutional Ownership
Full report →- ▼6 buying vs 7 selling
- ▼Held by funds -4.9 pts
- ▼Funds holding -2
- ●No superinvestor moves
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 20 | 22 | −9.1% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | 66.1% | 71.0% | −4.9 pts |
| New / increased | 3 / 3 | 22 / 0 | −72.7% |
| Reduced / sold out | 2 / 5 | 0 / 0 | – |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ELOX is in one of them and how their past ELOX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ELOX in an article yet. Here's the latest on the wider market.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals is a drug development company based in Arlington, Massachusetts. It is developing product candidates for rare genetic kidney and dermatologic diseases, with an approach that targets processes such as fibrosis, inflammation and proteinuria. Its candidates are still in development. If approved, they would be prescribed to patients by physicians.
- Headquarters
- Arlington, MA